nCS1 – Gene Therapy and Nanomedicine Application Note
Analysis of Gene Therapy Vectors and Nanomedicines with the Spectradyne nCS1
Accurate quantification of gene therapy vectors and nanomedicines is critical at all stages of research and product development—whether for characterizing a production step or obtaining an accurate titer before assessing bioactivity. Spectradyne’s nCS1 quantifies all types of nanoparticle-based therapeutics quickly and accurately, and requires only 3 microliters of the sample per measurement.
Figure 1 shows nCS1 measurements of a proprietary virus-based drug product as it progresses through three stages of purification. While each stage of purification increases the concentration of particles over a broad size range, a clear enrichment of virus product is obtained with the second stage. These measurements provided the manufacturer of this product with a highly detailed picture of the purification process, and insights for optimization that could not have been obtained with any other method.
Because the nCS1 uses an electrical method, not light scattering, to count and size nanoparticles it measures all particle types equally well. As a result, researchers count on the nCS1 every day to measure diverse range of gene therapy vectors and other nanomedicines, including:
- Lentivirus, retrovirus, HSV and others
- Lipid nanoparticles (LNPs)
- Polymeric nanoparticles
- Milled drug particles (API crystals)
The nCS1 provides powerful insights to these researchers that cannot be obtained by any other method.
More information on the Spectradyne nCS1 here.